EGFR tyrosine kinase inhibitors (TKIs) are used in the treatment of NSCLC harboring EGFR-TKI sensitizing pathogenic variants such as Ex19del and p.Leu858Arg [7–10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.